In the news

Find our most recent press releases and other media below. CONTACT US if you need more details, would like to set up an interview or are a media person on deadline.

Ann Arbor, MI (June 21, 2019) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today the launch of CE-IVD assays for Hepatitis B virus (HBV) and Hepatitis C virus (HCV). Hepatitis infections are more frequent in immunocompromised populations than in the general population with lower rates of spontaneous recovery...

If you’re in Savannah, Georgia this week for the American Society for Microbiology’s Clinical Virology Symposium, NeuMoDx™ teammate Jason has a message for you! Stop by booth #547 now through Wednesday, May 8 at #ASMCVS – we can’t wait to show you the future of molecular diagnostics.

NeuMoDx™ Molecular was recently at ECCMID displaying our NeuMoDx™ Molecular 288 System. Our system is capable of automated extraction and isolation of nucleic acids from multiple specimen types, as well as the automated amplification and detection of target nucleic acid sequences by fluorescence-based PCR. Listen to Jeff Williams, Chairman and CEO of NeuMoDx™ Molecular, explain why the NeuMoDx™ system is...

NeuMoDx™ platforms are built to handle large volumes of sample in an automated fashion, integrating the entire molecular diagnostic process from sample to result. Dr. Steven Young, Director of Research and Clinical Trials at TriCore Reference Laboratories, has been working with NeuMoDx™ on an invitro diagnostics test approved by the FDA, using our instrumentation. Let Dr....


We are excited to announce that QIAGEN has acquired all shares of NeuMoDx Molecular, Inc. The addition of NeuMoDx’s medium- and high-throughput molecular systems further expands QIAGEN’s portfolio of molecular diagnostics instruments, bolstering our leadership in automated molecular testing. We are proud to welcome NeuMoDx to our family of PCR solutions that make improvements in life possible.

To learn more, click here.